secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001628280-24-023064
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics reports Q1 2024 net loss of $11.7M; cash $90.3M; Takeda Phase 3 soticlestat data expected by Sep 2024
--------------------------------------------------------------------------------

- Net loss $11.7M ($0.17/share) vs $13.4M ($0.19) in Q1 2023; revenue $148K.
- Cash $90.3M as of Mar 31, 2024; expected to fund operations into H1 2026.
- Takeda completed Phase 3 trials for soticlestat in LGS and Dravet; topline data expected in H1 2024 fiscal year (by Sep 2024).
- OV888 (GV101) Phase 1 MAD complete; no serious AEs; Phase 2 in CCM expected H2 2024.
- Ovid retains 87% interest in soticlestat milestones (up to $660M) and tiered royalties up to 20%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000162828024023064/0001628280-24-023064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000162828024023064/ovid-20240513.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-023064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer